Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2014 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2013 Net Income-$138.75K-$138.75KN/M vs Q3 2013 EPS Diluted$0.00$0.00— vs Q3 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
-$127,943
—
ended Sep 30, 2014 · filed Nov 14, 2014 · 45 d after period end